{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:02:01Z","timestamp":1782975721071,"version":"3.54.5"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Tuberc."],"abstract":"<jats:p>\n                    Sequencing for drug-resistant tuberculosis (DR-TB) surveillance was established in Nigeria for the first time, demonstrating a nationally coordinated referral network for multi-disease sequencing services.\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    isolates previously identified as resistant to rifampicin and\/or isoniazid by genotypic or phenotypic drug susceptibility testing were selected proportionately across all six geopolitical zones in Nigeria. Programmatic use of sequence data for DR-TB surveillance was prioritized, demonstrating additional resistance detection and enhanced monitoring as new TB treatment regimens are scaled up. Sanger sequencing identified resistance to rifampicin and isoniazid missed by drug susceptibility tests routinely used in country, for 11% (5\/47) and 2% (1\/47) of isolates, respectively. This pilot study demonstrates feasibility and provides an example for programmatic implementation of integrated sequencing, supporting country efforts to strengthen genomic surveillance for DR-TB and improve prevention and control globally.\n                  <\/jats:p>","DOI":"10.3389\/ftubr.2026.1855903","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:35:40Z","timestamp":1782970540000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of sequencing-based surveillance for drug-resistant tuberculosis in Nigeria"],"prefix":"10.3389","volume":"4","author":[{"given":"Heather P.","family":"McLaughlin","sequence":"first","affiliation":[{"name":"Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Audu","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monday","family":"Tola","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika Kingsley","family":"Onwuamah","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Nigerian Institute of Medical Research","place":["Lagos, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Ogwu","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Atoe","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chioma Nneka","family":"Kunle-Ope","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Nigerian Institute of Medical Research","place":["Lagos, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isiyaku","family":"Ahmadu","sequence":"additional","affiliation":[{"name":"National Tuberculosis Reference Laboratory","place":["Zaria, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Gowon","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Meshak","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosunmola","family":"Iwakun","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinedu Ejianya","family":"Ude","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modupe","family":"Abiona","sequence":"additional","affiliation":[{"name":"Institute of Human Virology Nigeria","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abidemi Esther","family":"Momoh","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Nigerian Institute of Medical Research","place":["Lagos, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temiloluwa","family":"Ore","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Nigerian Institute of Medical Research","place":["Lagos, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinenye Angela","family":"Ogbu","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Nigerian Institute of Medical Research","place":["Lagos, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope Abigail","family":"Abiodun","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Nigerian Institute of Medical Research","place":["Lagos, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Dawson","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Hall-Eidson","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnaemeka C.","family":"Iriemenam","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McPaul","family":"Okoye","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Adesigbin","sequence":"additional","affiliation":[{"name":"National Tuberculosis and Leprosy Control Programme, Federal Ministry of Health","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obioma","family":"Chijioke-Akaniro","sequence":"additional","affiliation":[{"name":"National Tuberculosis and Leprosy Control Programme, Federal Ministry of Health","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elom","family":"Emeka","sequence":"additional","affiliation":[{"name":"National Tuberculosis and Leprosy Control Programme, Federal Ministry of Health","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyaike","family":"Chukwuma","sequence":"additional","affiliation":[{"name":"National Tuberculosis and Leprosy Control Programme, Federal Ministry of Health","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","article-title":"Drug-resistant tuberculosis: a persistent global health concern","volume":"22","author":"Farhat","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"B2","year":""},{"key":"B3","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.2147\/IDR.S381643","article-title":"Rapid molecular assays for the diagnosis of drug-resistant Tuberculosis","volume":"15","author":"Nandlal","year":"2022","journal-title":"Infect Drug Resist"},{"key":"B4","volume-title":"Guidance for the Surveillance of Drug Resistance in Tuberculosis","year":"2020"},{"key":"B5","volume-title":"National Strategic Plan for Tuberculosis Control, 2021\u20132025","year":"2021"},{"key":"B6","volume-title":"Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis","year":"2018"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0232343","DOI":"10.1371\/journal.pone.0232343","article-title":"Detection of drug resistant Mycobacterium tuberculosis by high-throughput sequencing of DNA isolated from acid fast bacilli smears","volume":"15","author":"Rowneki","year":"2020","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3343\/alm.2018.38.6.563","article-title":"Delamanid, bedaquiline, and linezolid Minimum inhibitory concentration distributions and resistance related gene mutations in multidrug-resistant and extensively drug-resistant Tuberculosis in Korea","volume":"38","author":"Yang","year":"2018","journal-title":"Ann Lab Med"},{"key":"B9","volume-title":"Catalogue of Mutations in Mycobacterium Tuberculosis Complex and Their Association with Drug Resistance","year":"2021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1128\/JCM.02741-12","article-title":"Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations","volume":"51","author":"Rigouts","year":"2013","journal-title":"J Clin Microbiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"720436","DOI":"10.3389\/fmicb.2021.720436","article-title":"Whole-Genome sequencing to identify missed rifampicin and isoniazid resistance among Tuberculosis isolates\u2014Chennai, India, 2013\u20132016","volume":"12","author":"Tamilzhalagan","year":"2021","journal-title":"Front Microbiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/pathogens13010027","article-title":"Rapid diagnosis of drug-resistant Tuberculosis-opportunities and challenges","volume":"13","author":"Naidoo","year":"2024","journal-title":"Pathogens"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1473-3099(24)00263-9","article-title":"Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"24","author":"Schwab","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B14","volume-title":"Use of Next-Generation Sequencing for the Surveillance of Drug-Resistant Tuberculosis: An Implementation Manual","year":"2023"},{"key":"B15","volume-title":"WHO Consolidated Guidelines on Tuberculosis: Module 3: Diagnosis: Rapid Diagnostics for Tuberculosis Detection","year":"2024"}],"container-title":["Frontiers in Tuberculosis"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftubr.2026.1855903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:35:42Z","timestamp":1782970542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftubr.2026.1855903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":15,"alternative-id":["10.3389\/ftubr.2026.1855903"],"URL":"https:\/\/doi.org\/10.3389\/ftubr.2026.1855903","relation":{},"ISSN":["2813-7868"],"issn-type":[{"value":"2813-7868","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1855903"}}